Results:
Patients had median levels of HDL-C (33.5 mg/dL), apoA-I (116 mg/dL), MPO (110 pmol/L) and arylesterase (102 μmol/min/mL). More MACE was observed with increasing MPO and decreasing levels of HDL-C, apoA-I and arylesterase. High levels of HDL-C, apoA-I and arylesterase predicted cardioprotection at all MPO levels (p<0.05). Combining MPO with HDL-C, apoA-I or arylesterase resulted in the greatest discrimination of CV risk. Combining the low quartile of HDL-C, apoA-I or arylesterase with the high MPO quartile resulted in the highest MACE rate (20.1-20.8%) while the high quartile of HDL markers and low MPO quartile was associated with the lowest MACE rate (6.1-7.6%, p<0.03). Patients with low arylesterase/high MPO had a >10-fold greater rate of mortality than patients with high arylesterase/low MPO (15.2 v 1.3%, p<0.05).
Conclusion:
Measures of HDL quantity and quality predict CV outcome at all MPO levels. Combining MPO and HDL markers improves CV risk prediction. 
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